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INTRODUCTION
It is known that 2 ,3 -dideoxynucleoside analogues commonly used in HIV/AIDS therapy are poorly phosphorylated to their active forms-5 -triphosphates-in monocyte derived macrophages (MDM) and, therefore, their therapeutic effects are limited. Direct introduction of nucleotides into animal cells essentially does not occur. To overcome these limitations, some 5 ,5 -P 1 ,P 2 dinucleotides were previously synthesized; it was shown that after encapsulation in erythrocytes (RBC) they protected in vitro human macrophages from HIV-1 infection. [1] Such compounds are more soluble in aqueous media than the parent nucleosides, and show better, as compared with nucleosides, penetration into the cell in undegraded form. 5 ,5 -P 1 ,P 2 -dinucleotides undergo intracellular hydrolysis by dinucleotide New Pyrimidine P 1 ,P 2 -Dinucleotides 439 pyrophosphatase to nucleoside 5 -monophosphates, which may be further phosphorylated by kinases to 5 -triphosphates. [2] Analogues of 3 -fluorothymidine thiated at the heterocyclic moiety are selective inhibitors of HIV-1. [3] To enhance their solubility in water and penetration into T-lymphocytes, we decided to synthesize thiated homoand hetero-5 ,5 -P 1 ,P 2 -dinucleotides and investigate, without encapsulation in RBC, their inhibitory activity toward HIV-1 in CEM-T4 cells.
RESULTS AND DISCUSSION
Chemistry 5 -Mononucleotides of 3 -azidothymidine and thiated analogues of 3 -fluorothymidine were prepared from appropriate nucleosides in reaction with POCl 3 , 1,2,4-triazole and triethylamine. 1-[(2-Hydroxyethoxy)methyl-5-propyl-6-phenylselenenyl]uracil phosphate was synthesized with the use of Yoshikawa procedure, employing direct phosphorylation with POCl 3 in trimethylphosphate.
P 1 ,P 2 -homodinucleotides 3 and 4 were synthesized by condensation of 5 -mononucleotides in the presence of tosyl chloride (Scheme 1). P 1-3 -fluoro-2-thiothymidine-P 2-3 -azidothymidine pyrophosphate (6) was prepared with the use of a multistep procedure, involving the conversion of 2 ,3 -dideoxy-3 -fluoro-2-thiothymidine 5 -mononucleotide to P 1-3 -fluoro-2-thiothymidine-5 -P 2 -diphenylpyrophosphate followed by condensation with AZTMP (Scheme 2). 5 -Mononucleotide of 2 ,3 -dideoxy-3 -fluoro-2-thiothymidine was converted into morpholine derivative in reaction with morpholine and 1,3-dicyclohexylcarbodiimide in t-BuOH/H 2 O. Coupling of 3 -fluoro-2-thiothymidine 5 -monophosphate morpholidate with tri-n-butylammonium salt of 1-[(2-hydroxyethoxy)methyl-5-propyl-6-phenylselenenyl]uracil phosphate led to heterodinucleotide 8 (Scheme 3). 
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SCHEME 2
Synthesis of P 1-3 -fluoro-2-thiothymidine-P 2-3 -azidothymidine pyrophosphate (6).
8 SCHEME 3 Synthesis of P 1-3 -fluoro-2-thiothymidine-P 2-1-[(2-hydroxyethoxy)methyl-5-propyl-6-phenylselenenyl]uracil pyrophosphate (8).
Biology
New P 1 ,P 2 dinucleotides 3, 4, and 6 cells exhibited potent antiviral activity in CEM-T4 (ED 50 15, 45, and 5 nM, respectively). Lower activity of 8 (ED 50 200 nM) is most likely caused by larger nonpolar aryloseleno-substituent at position 2 of uracil ring, while very high activity of compound 6 is probably due to the presence of AZT as a part of the dinucleotide molecule.
No cytotoxicity was observed in CEM-T4 cells at the highest tested concentration (100 µM), so that the therapeutic indexes were higher than 4,666-14,000.
To explain the mode of the antiviral action of the above mentioned thiated P 1 ,P 2 -pyrimidine analogues, corresponding nucleoside 5 -triphosphates were synthesized, and their interactions with HIV-1 recombinant reverse transcriptase (HIV-1 RT) were investigated and compared with those of the P 1 ,P 2 -dinucleotide analogues. The most active inhibitors were 5 -triphosphates of 2 ,3 -dideoxy-3 -fluoro-2-thiothymidine and 2 ,3 -dideoxy-3 -fluoro-4-thiothymidine, with inhibitory activity (IC 50 ) 0.17 µM and 0.2 µM, respectively, while the corresponding P 1 ,P 2 -dinucleotides 3 and 4 exhibited somewhat lower inhibitory activities (IC 50 0.2 and 0.9 µM, respectively). The obtained results show that antiviral activities of thiated pyrimidine P 1 ,P 2 -dinucleotides are only to some extent correlated with HIV RT inhibition, and rather the 5 -triphosphates, resulting from the metabolism of 5 -monophosphates, are responsible for the antiviral activity.
EXPERIMENTAL

General Procedures
High resolution . 5 -Monophosphate of 2 ,3 -dideoxy-3 -fluoro-2-thiothymidine (1) (51 mg, 0.14 mmol) was transformed into tri-n-butylammonium salt and dissolved in 5 mL of dry DMF. To this solution was added 0.5 mL of dry pyridine, catalytic amount of 4-dimethylaminopyridine and tosyl chloride (78 mg, 0.4 mmol). The solution was stirred at room temperature for 24 hours and 2 mL of water was added. After evaporation of the solvents the product was purified by ion-exchange column chromatography with a DEAE-Sephadex A-25 resign with a linear gradient (0-0.4 M) of aqueous triethylammonium bicarbonate buffer as the mobile phase. The homogenous fractions containing pure pyrophosphate were pooled and concentrated under reduced pressure. The product was dissolved in a small amount of methanol and solution of 100 mg NaI in 5 mL of acetone was added. The precipitated sodium salt was filtered off, washed several times with acetone, and dried over P 2 Compound 1 (68 mg, 0.2 mmol) was converted into tri-n-butylammonium salt (free acid was dissolved in 3 mL of methanol with 0.4 mL tri-n-butylamine and stirred for 30 minutes) and dissolved in the mixture of dry 1,4-dioxane (1 mL) and DMF (0.25 mL). Diphenyl chlorophosphate (42 µL, 0.2 mmol) and tri-n-butylamine (55 µL, 0.23 mmol) was added and stirred in room temperature for 3 hours. After evaporation of the solvents diethyl ether (10 mL) was added, and the reaction mixture was left standing for 1 hour in refrigerator. Diethyl ether was decanted, and the traces of ether were removed by evaporation with dioxane. Resulting P 1 -nucleoside-5 -P 2 -diphenylpyrophosphate 5 was dissolved in 1 mL of dry pyridine and triethylammonium salt of 3 -azido-2 ,3 -dideoxytymidine 5 -monophosphate (69.4 mg, 0.2 mmol) was added and stirred in room temperature for 18 hours. Reaction mixture was evaporated to dryness under reduced pressure and extracted two times with diethyl ether. The residue was purified by ion-exchange column chromatography with a DEAE-Sephadex A-25 resign with a linear gradient (0-0.4 M) of aqueous triethylammonium bicarbonate buffer as the mobile phase. The fractions containing pure pyrophosphate were pooled and concentrated under reduced pressure and converted to sodium salt. Yield: 17.3 mg (12%); TLC R f 0.67; To the solution of 1 (44.2 mg, 0.13 mmol) in 2 mL of water tert-butanol (2 mL) and morpholine (45 µL, 0.52 mmol) were added, and reaction mixture was heated at 90
• C. 1,3-Dicyclohexylcarbodiimide (107.5 mg, 0.52 mmol) in 3 mL of tert-butanol was added and the reaction mixture was stirred and heated at 90
• C for 3 hours. After this time 2 mL of water was added and the mixture was extracted with diethyl ether (3 × 10 mL). The combined organic fractions were dried over Na 2 SO 4 and evaporated under reduced pressure New Pyrimidine P 1 ,P 2 -Dinucleotides 443 to syrup. Received morpholine derivative of o-P 1 -nucleosidephosphate 7 was dissolved in 1 mL of anhydrous pyridine, and tri-n-butylammonium salt of 1-[(2-hydroxyethoxy)methyl]-6-phenylselenenyl-5-propyluracil 5 -monophosphate (50 mg, 0.11 mmol) was added. The mixture was stirred at room temperature for 18 hours. After evaporation of the solvents the residue was extracted two times with diethyl ether. The residue was purified by ion-exchange column chromatography with a DEAE-Sephadex A-25 resign with a linear gradient (0-0.4 M) of aqueous triethylammonium bicarbonate buffer as the mobile phase. The fractions containing pure pyrophosphate were pooled and concentrated under reduced pressure and converted to sodium salt. Yield: 13.5 mg (15%); TLC R f 0. 
Inhibition of HIV-1 Virus Replication
Antiviral activity was determined as follows: CEM-T4 cells (kindly provided by NIH AIDS Research and Reference Program) inoculated with HIV-1 (syncytia inducing phenotype) were cultured for up to 10 days in 96 well culture plate with various concentrations of the tested compounds in triplicate. The media over the cell cultures were collected at various time intervals, and the amounts of p24 protein were determined. The efficacy of inhibition of HIV-1 replication by the tested compounds was compared and related to the control culture grown in standard medium, as well as to cells cultured in media enriched with known amounts of AZT.
The cytotoxicity of the investigated compounds was tested in CEM-T4 cells. After 10 days of culture at various concentrations of the tested compounds, the cell viability was determined by the standard MTT method.
HIV-1 Reverse Transcriptase Assay
The activity of HIV-1 RT was determined using a colorimetric method involving incorporation of digoxigenin-and biotin-labeled dUTP into DNA [4] . Standard reaction mixture contained 46 mM Tris-HCl (pH 7.8), 9.2 mM DTT, 27.5 mM MgCl 2 , 266 mM KCl, 0.05% Triton X-100, 1.25 mg/m BSA, 0.075 mM EDTA, 0.1 mM poly(A)oligo(dT) 15 , digoxigenin-and biotinlabeled nucleotides dUTP/dTTP (10µM), 3 µL RT (30 mU/µL), and 20 µL (0.01-5 µM) of inhibitor solution. The mixture was incubated at 37
• C for 1 hour, and unreacted substrates were washed out. Antibodies against digoxigenin (200 µL) conjugated with peroxidase (200 mU/mL) were added and
